Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M400×M100B-vedotin
- Development stage
- Preclinical
- Lead developer
- GO Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
M400×M100B-vedotin is a next-generation bispecific antibody-drug conjugate (ADC) developed by GO Therapeutics. It targets tumor-specific Tn-glycoepitopes on MUC1 and MUC4, which are neoepitopes generated by altered O-glycosylation in epithelial cancers and are largely absent from healthy tissues. The ADC is engineered as a site-specific conjugate using an mc-vc-PAB-MMAE (vedotin) linker-payload system with a drug-to-antibody ratio (DAR) of 2. By simultaneously recognizing MUC1-Tn and MUC4-Tn, M400×M100B-vedotin aims to overcome tumor heterogeneity and improve selectivity in solid tumors. Preclinical studies have demonstrated potent cytotoxicity and tumor regressions in models of breast, lung, ovarian, pancreatic, and gastrointestinal cancers.
- Other names
- MUC1/MUC4 bispecific ADCMUC1/MUC4-targeted bispecific ADC
02
Targets
MUC4 (Mucin-4)MUC1 (Mucin-1 Antigen)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on M400×M100B-vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M400×M100B-vedotin.